Concert moves towards agreement for cystic fibrosis assets
Concert Pharmaceuticals Inc. has received a second request from the Federal Trade Commission for the acquisition of CTP-656, as well as other options for cystic fibrosis treatment, produced by Vertex Pharmaceuticals Inc. Read More »